273 related articles for article (PubMed ID: 2138079)
21. Growth and pubertal development during and after treatment with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty.
Oostdijk W; Gevers EF; Drop SL; Rikken B; Hümmelink R; Partsch CJ; Sippell WG
Horm Res; 1991; 36(3-4):121-5. PubMed ID: 1840141
[TBL] [Abstract][Full Text] [Related]
22. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
[TBL] [Abstract][Full Text] [Related]
23. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty.
Comite F; Pescovitz OH; Rieth KG; Dwyer AJ; Hench K; McNemar A; Loriaux DL; Cutler GB
J Clin Endocrinol Metab; 1984 Nov; 59(5):888-92. PubMed ID: 6434587
[TBL] [Abstract][Full Text] [Related]
24. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
25. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
26. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
[TBL] [Abstract][Full Text] [Related]
27. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
[TBL] [Abstract][Full Text] [Related]
28. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
29. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate.
Verrotti A; Ferrari M; Sabatino G; Morgese G; Chiarelli F
Gynecol Endocrinol; 1997 Aug; 11(4):243-50. PubMed ID: 9272420
[TBL] [Abstract][Full Text] [Related]
30. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome.
Foster CM; Comite F; Pescovitz OH; Ross JL; Loriaux DL; Cutler GB
J Clin Endocrinol Metab; 1984 Oct; 59(4):801-5. PubMed ID: 6434582
[TBL] [Abstract][Full Text] [Related]
31. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
[TBL] [Abstract][Full Text] [Related]
32. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
33. [Growth, development and prediction of body height in children with central precocious puberty after 3 years of therapy with Decapeptyl-Depot, a slow-releasing GnRH agonist].
Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
Cesk Pediatr; 1994; 49(1):7-12. PubMed ID: 8124755
[TBL] [Abstract][Full Text] [Related]
34. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
35. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.
Tatò L; Saggese G; Cavallo L; Antoniazzi F; Corrias A; Pasquino AM; Cisternino M
Horm Res; 1995; 44 Suppl 3():49-54. PubMed ID: 8719441
[TBL] [Abstract][Full Text] [Related]
36. Serum Levels of Thyroid Stimulating Hormone and Luteinizing Hormone Are Decreased in Girls with Central Precocious Puberty after 12-Month GnRH Agonist Treatment.
Kim YJ; Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
Tohoku J Exp Med; 2020 Nov; 252(3):193-197. PubMed ID: 33087637
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic effectiveness of the gonadotropin releasing hormone analogue D-Trp-6-LHRH in the treatment of precocious puberty].
Rodríguez Arnao MD; Rodríguez Sánchez MD; González Sicilia IG; Lorenzo Navarro L; Nieto Cuartero J; Schally AV; Rodríguez Arnao J; García Centenera JA; Gómez Pan A
An Esp Pediatr; 1988 Dec; 29(6):445-51. PubMed ID: 2977533
[TBL] [Abstract][Full Text] [Related]
38. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
[TBL] [Abstract][Full Text] [Related]
39. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
